Trial Profile

A Long-term Monitoring Study to Evaluate the Persistence of Direct Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Virological Response (SVR) in Patients Treated With DAA Containing Regimens for Chronic Hepatitis C Infections (CHC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mericitabine (Primary) ; Antivirals; Boceprevir; Danoprevir; Setrobuvir; Telaprevir
Indications Hepatitis C
Focus Therapeutic Use
Sponsors Roche

10 Mar 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com